Can-Fite BioPharma (NYSE:CANF) Given Buy Rating at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Can-Fite BioPharma (NYSE:CANF) in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has a $10.00 price target on the stock.

Other equities analysts also recently issued research reports about the stock. HC Wainwright reissued a “buy” rating and issued a $18.00 price objective on shares of Can-Fite BioPharma in a research note on Tuesday, November 12th. StockNews.com began coverage on shares of Can-Fite BioPharma in a research note on Thursday, February 27th. They issued a “sell” rating for the company.

Can-Fite BioPharma Stock Performance

Shares of CANF stock opened at $1.72 on Monday. The firm’s 50-day moving average is $1.58 and its 200-day moving average is $1.94. The stock has a market cap of $6.09 million, a price-to-earnings ratio of -0.96 and a beta of 1.33. Can-Fite BioPharma has a 52-week low of $1.29 and a 52-week high of $4.69.

Hedge Funds Weigh In On Can-Fite BioPharma

An institutional investor recently bought a new position in Can-Fite BioPharma stock. BNP Paribas Financial Markets bought a new position in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 25,185 shares of the company’s stock, valued at approximately $41,000. BNP Paribas Financial Markets owned about 0.71% of Can-Fite BioPharma as of its most recent SEC filing. Institutional investors own 21.00% of the company’s stock.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.